Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03519256 · ClinicalTrials.gov registry record · Phase 2
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT03519256 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 142 participants.
The verdict
NCT03519256, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL BCG
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03519256
The ClinicalTrials.gov registry entry for NCT03519256 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03519256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03519256 about?
NCT03519256 is a clinical study titled "A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder". A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
What is the current status of trial NCT03519256?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2018-08-02. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT03519256?
The interventions under investigation include: Nivolumab (BIOLOGICAL), BCG (BIOLOGICAL), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT03519256?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.